# [KJ-INT-002] BE Study

> **NCT03509831** · PHASE1 · UNKNOWN · sponsor: **Kukje Pharma** · enrollment: 37 (actual)

## Conditions studied

- Gastritis

## Interventions

- **DRUG:** INT-2150
- **DRUG:** Irsogladine maleate 2 mg+Nizatidine 150 mg

## Key facts

- **NCT ID:** NCT03509831
- **Lead sponsor:** Kukje Pharma
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-02
- **Primary completion:** 2018-01-24
- **Final completion:** 2018-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509831, "[KJ-INT-002] BE Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03509831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*